Skip to main content
Top
Published in: Current Treatment Options in Oncology 3/2014

01-09-2014 | Sarcoma (SH Okuno, Section Editor)

Surgical Treatment of Sarcomas of the Spine

Authors: Ali K. Ozturk, MD, Ziya L. Gokaslan, MD, Jean-Paul Wolinsky, MD

Published in: Current Treatment Options in Oncology | Issue 3/2014

Login to get access

Opinion statement

Primary sarcomas of the spine are rare diseases and include osteosarcoma, chondrosarcoma, chordoma, and Ewing’s sarcoma. Surgery for these lesions remains an important part of their treatment. Strong evidence exists for the en bloc resection of chondrosarcoma and chordoma since these lesions respond poorly to both chemotherapy and radiation. Weaker but important evidence suggests that osteosarcoma and Ewing’s sarcoma may also benefit from wide excisions, but after the application of neoadjuvant therapy, which may significantly aid the surgical process as well as independently prolong the survival. The unacceptable morbidity associated with damage to the neural elements makes resection with wide margins difficult in the spine. Nevertheless, this can be achieved in many circumstances and can, on occasion, lead to long term disease-free survival and even cure. There are numerous techniques described for en bloc resections in the mobile spine and pelvis and these vary widely for the region of the spine involved and the preferences of the surgeon. There are constant principles that do apply to all cases. We think of these surgeries as consisting of 2 stages which can be done in 1 or multiple operations. In the first phase, a corridor free of tumor is removed from the bone and the neural elements to be protected are dissected free from surrounding tissues. In the second phase, the tumor and a margin of normal tissue is circumferentially dissected and delivered while sparing the neural structures. Patient selection, in terms of age, overall disease burden, personal preferences, and comorbidities need to be carefully taken into account to optimize the risk benefit ratio. Sarcomas of the spine are a challenging group of lesions to treat but they can also be the most rewarding. Our newly acquired insight into the pathogenesis of these lesions, as well as improved surgical techniques combined with better neoadjuvant and adjuvant therapies are leading to longer survival times as well as long term disease free survivors.
Literature
1.
go back to reference Shives TC, Dahlin DC, Sim FH, Pritchard DJ, Earle JD. Osteosarcoma of the spine. J Bone Joint Surg Am. 1986;68:660–8.PubMed Shives TC, Dahlin DC, Sim FH, Pritchard DJ, Earle JD. Osteosarcoma of the spine. J Bone Joint Surg Am. 1986;68:660–8.PubMed
3.•
go back to reference Mirabello L, Troisi RJ, Savage S. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531–43. This article is one of the few articles surveying a large database about the incidence and survival rates for osteosarcoma.PubMedCentralPubMedCrossRef Mirabello L, Troisi RJ, Savage S. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531–43. This article is one of the few articles surveying a large database about the incidence and survival rates for osteosarcoma.PubMedCentralPubMedCrossRef
4.
go back to reference Hauben EI, Arends J, Vandenbroucke JP, van Asperen CJ, Van Marck E, Hogendoorn PC. Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. Eur J Hum Genet. 2003;11:611–8.PubMedCrossRef Hauben EI, Arends J, Vandenbroucke JP, van Asperen CJ, Van Marck E, Hogendoorn PC. Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. Eur J Hum Genet. 2003;11:611–8.PubMedCrossRef
5.
go back to reference Boriani S, De Iure F, Bandiera S, Campanacci L, Biagini R, Di Fiore M, et al. Chondrosarcoma of the mobile spine: report on 22 cases. Spine. 2000;25:804–12.PubMedCrossRef Boriani S, De Iure F, Bandiera S, Campanacci L, Biagini R, Di Fiore M, et al. Chondrosarcoma of the mobile spine: report on 22 cases. Spine. 2000;25:804–12.PubMedCrossRef
6.
go back to reference Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am. 2009;91:1063–72.PubMedCrossRef Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am. 2009;91:1063–72.PubMedCrossRef
7.
go back to reference Brien EW, Mirra JM, Kerr R. Benign and malignant cartilage tumors of bone and joint: their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. I. The intramedullary cartilage tumors. Skelet Radiol. 1997;26:325–53.CrossRef Brien EW, Mirra JM, Kerr R. Benign and malignant cartilage tumors of bone and joint: their anatomic and theoretical basis with an emphasis on radiology, pathology and clinical biology. I. The intramedullary cartilage tumors. Skelet Radiol. 1997;26:325–53.CrossRef
8.
go back to reference de Andrea CE, Reijnders CM, Kroon HM, de Jong D, Hogendoorn PC, Szuhai K, et al. Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT. Oncogene. 2012;31:1095–104.PubMedCrossRef de Andrea CE, Reijnders CM, Kroon HM, de Jong D, Hogendoorn PC, Szuhai K, et al. Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT. Oncogene. 2012;31:1095–104.PubMedCrossRef
9.
go back to reference Bovee JV, Cleton-Jansen AM, Kuipers-Dijkshoorn NJ, van den Broek LJ, Taminiau AH, Cornelisse CJ, et al. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Gene Chromosome Cancer. 1999;26:237–46.CrossRef Bovee JV, Cleton-Jansen AM, Kuipers-Dijkshoorn NJ, van den Broek LJ, Taminiau AH, Cornelisse CJ, et al. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Gene Chromosome Cancer. 1999;26:237–46.CrossRef
10.
go back to reference Suva ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, et al. Identification of cancer stem cells in Ewing’s sarcoma. Cancer Res. 2009;69:1776–81.PubMedCrossRef Suva ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, et al. Identification of cancer stem cells in Ewing’s sarcoma. Cancer Res. 2009;69:1776–81.PubMedCrossRef
11.•
go back to reference Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell. 2007;11:421–9. This article provides vital information regarding the molecular features of Ewing’s Sarcoma.PubMedCrossRef Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell. 2007;11:421–9. This article provides vital information regarding the molecular features of Ewing’s Sarcoma.PubMedCrossRef
12.
go back to reference van den Berg H, Dirksen U, Ranft A, Jurgens H. Ewing tumors in infants. Pediatr Blood Cancer. 2008;50:761–4.PubMedCrossRef van den Berg H, Dirksen U, Ranft A, Jurgens H. Ewing tumors in infants. Pediatr Blood Cancer. 2008;50:761–4.PubMedCrossRef
13.
go back to reference Jawad MU, Cheung MC, Min ES, Schneiderbauer MM, Koniaris LG, Scully SP. Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973–2005. Cancer. 2009;115:3526–36.PubMedCrossRef Jawad MU, Cheung MC, Min ES, Schneiderbauer MM, Koniaris LG, Scully SP. Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973–2005. Cancer. 2009;115:3526–36.PubMedCrossRef
14.
go back to reference de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma. J Clin Oncol. 1998;16:1248–55.PubMed de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma. J Clin Oncol. 1998;16:1248–55.PubMed
15.
go back to reference Tirabosco R, Mangham DC, Rosenberg AE, Vujovic S, Bousdras K, Pizzolitto S, et al. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol. 2008;32:572–80.PubMedCrossRef Tirabosco R, Mangham DC, Rosenberg AE, Vujovic S, Bousdras K, Pizzolitto S, et al. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol. 2008;32:572–80.PubMedCrossRef
16.
go back to reference McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control. 2001;12:1–11.PubMedCrossRef McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control. 2001;12:1–11.PubMedCrossRef
17.
go back to reference Shalaby A, Presneau N, Ye H, Halai D, Berisha F, Idowu B, et al. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol. 2011;223:336–46.PubMedCrossRef Shalaby A, Presneau N, Ye H, Halai D, Berisha F, Idowu B, et al. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol. 2011;223:336–46.PubMedCrossRef
18.
go back to reference Phadke DM, Lucas DR, Madan S. Fine-needle aspiration biopsy of vertebral and intervertebral disc lesions: specimen adequacy, diagnostic utility, and pitfalls. Arch Pathol Lab Med. 2001;125:1463–8.PubMed Phadke DM, Lucas DR, Madan S. Fine-needle aspiration biopsy of vertebral and intervertebral disc lesions: specimen adequacy, diagnostic utility, and pitfalls. Arch Pathol Lab Med. 2001;125:1463–8.PubMed
19.••
go back to reference Mukherjee D, Chaichana KL, Gokaslan ZL, Aaronson O, Cheng JS, McGirt MJ. Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003. J Neurosurg Spine. 2011;14:143–50. This article once again surveys the SEER database for the survival of patients with primary osseous neoplasms. Given the rarity of these lesions, much of what is known regarding the epidemiology and prognosis of these lesions comes from this database.PubMedCrossRef Mukherjee D, Chaichana KL, Gokaslan ZL, Aaronson O, Cheng JS, McGirt MJ. Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003. J Neurosurg Spine. 2011;14:143–50. This article once again surveys the SEER database for the survival of patients with primary osseous neoplasms. Given the rarity of these lesions, much of what is known regarding the epidemiology and prognosis of these lesions comes from this database.PubMedCrossRef
20.••
go back to reference Mukherjee D, Chaichana KL, Parker SL, Gokaslan ZL, McGirt MJ. Association of surgical resection and survival in patients with malignant primary osseous spinal neoplasms from the Surveillance, Epidemiology, and End Results (SEER) database. Eur Spine J. 2013;22:1375–82. This article once again surveys the SEER database for the survival of patients with primary osseous neoplasms. Given the rarity of these lesions, much of what is known regarding the epidemiology and prognosis of these lesions comes from this database. PubMedCentralPubMedCrossRef Mukherjee D, Chaichana KL, Parker SL, Gokaslan ZL, McGirt MJ. Association of surgical resection and survival in patients with malignant primary osseous spinal neoplasms from the Surveillance, Epidemiology, and End Results (SEER) database. Eur Spine J. 2013;22:1375–82. This article once again surveys the SEER database for the survival of patients with primary osseous neoplasms. Given the rarity of these lesions, much of what is known regarding the epidemiology and prognosis of these lesions comes from this database. PubMedCentralPubMedCrossRef
21.•
go back to reference York JE, Berk RH, Fuller GN, Rao JS, Abi-Said D, Wildrick DM, et al. Chondrosarcoma of the spine: 1954 to 1997. J Neurosurg. 1999;90:73–8. These articles provide significant evidence for the en bloc resection of chrodoma and chondrosarcoma.PubMed York JE, Berk RH, Fuller GN, Rao JS, Abi-Said D, Wildrick DM, et al. Chondrosarcoma of the spine: 1954 to 1997. J Neurosurg. 1999;90:73–8. These articles provide significant evidence for the en bloc resection of chrodoma and chondrosarcoma.PubMed
22.•
go back to reference York JE, Kaczaraj A, Abi-Said D, Fuller GN, Skibber JM, Janjan NA, et al. Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery. 1999;44:74–9. discussion 79–80. These articles provide significant evidence for the en bloc resection of chrodoma and chondrosarcoma. York JE, Kaczaraj A, Abi-Said D, Fuller GN, Skibber JM, Janjan NA, et al. Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery. 1999;44:74–9. discussion 79–80. These articles provide significant evidence for the en bloc resection of chrodoma and chondrosarcoma.
23.
go back to reference Bacci G, Longhi A, Briccoli A, Bertoni F, Versari M, Picci P. The role of surgical margins in treatment of Ewing’s sarcoma family tumors: experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2006;65:766–72.PubMedCrossRef Bacci G, Longhi A, Briccoli A, Bertoni F, Versari M, Picci P. The role of surgical margins in treatment of Ewing’s sarcoma family tumors: experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2006;65:766–72.PubMedCrossRef
24.
go back to reference Bielack S, Carrle D, Casali PG, Group EGW. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:137–9.PubMed Bielack S, Carrle D, Casali PG, Group EGW. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:137–9.PubMed
25.
go back to reference Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing’s Sarcoma Study CESS 86. J Clin Oncol. 2001;19:1818–29.PubMed Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing’s Sarcoma Study CESS 86. J Clin Oncol. 2001;19:1818–29.PubMed
26.
go back to reference Oberlin O, Deley MC, Bui BN, Gentet JC, Philip T, Terrier P, et al. Prognostic factors in localized Ewing’s tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer. 2001;85:1646–54.PubMedCentralPubMedCrossRef Oberlin O, Deley MC, Bui BN, Gentet JC, Philip T, Terrier P, et al. Prognostic factors in localized Ewing’s tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer. 2001;85:1646–54.PubMedCentralPubMedCrossRef
27.
go back to reference Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am. 1998;80:1020–33.PubMedCrossRef Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am. 1998;80:1020–33.PubMedCrossRef
28.
go back to reference Nooij MA, Whelan J, Bramwell VH, Taminiau AT, Cannon S, Hogendoorn PC, et al. Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. Eur J Cancer. 2005;41:225–30.PubMedCrossRef Nooij MA, Whelan J, Bramwell VH, Taminiau AT, Cannon S, Hogendoorn PC, et al. Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. Eur J Cancer. 2005;41:225–30.PubMedCrossRef
29.
go back to reference Stea B, Cavazzana A, Kinsella TJ. Small-cell osteosarcoma: correlation of in vitro and clinical radiation response. Int J Radiat Oncol Biol Phys. 1988;15:1233–8.PubMedCrossRef Stea B, Cavazzana A, Kinsella TJ. Small-cell osteosarcoma: correlation of in vitro and clinical radiation response. Int J Radiat Oncol Biol Phys. 1988;15:1233–8.PubMedCrossRef
Metadata
Title
Surgical Treatment of Sarcomas of the Spine
Authors
Ali K. Ozturk, MD
Ziya L. Gokaslan, MD
Jean-Paul Wolinsky, MD
Publication date
01-09-2014
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 3/2014
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-014-0290-8

Other articles of this Issue 3/2014

Current Treatment Options in Oncology 3/2014 Go to the issue

Upper Gastrointestinal Cancers (L Rajdev, Section Editor)

Targeting the mTOR Signaling Pathway in Neuroendocrine Tumors

Lower Gastrointestinal Cancers (AB Benson, Section Editor)

Liver-Directed Treatments for Metastatic Colorectal Cancer

Lower Gastrointestinal Cancers (AB Benson, Section Editor)

Chinese Herbal Medicines in the Treatment of IBD and Colorectal Cancer: A Review

Lower Gastrointestinal Cancers (AB Benson, Section Editor)

Optimal Treatment Strategies for Anal Cancer

Upper Gastrointestinal Cancers (L Rajdev, Section Editor)

The Role of 18F-FDG PET Imaging in Upper Gastrointestinal Malignancies

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine